<DOC>
	<DOC>NCT02443116</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.</brief_summary>
	<brief_title>Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Males or females, between 18 and 75 years of age, inclusive Histologically confirmed NASH diagnosis Clinically significant acute or chronic liver disease Prior liver transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>